Clarissa Luiza Dalla Bernardina Carvalho, Luciena Cegatto Martins Ortigosa
Abstract
The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.
Pharmacology, Toxicology and Pharmaceutical Science
2
10%
Agricultural and Biological Sciences
2
10%
Psychology
2
10%
Other
2
10%
Unknown
4
20%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2014.
All research outputs
#17,729,864
of 25,986,827 outputs
Outputs from Anais Brasileiros de Dermatologia
#4
of 6 outputs
Outputs of similar age
#205,825
of 321,766 outputs
Outputs of similar age from Anais Brasileiros de Dermatologia
#17
of 24 outputs
Altmetric has tracked 25,986,827 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6 research outputs from this source. They receive a mean Attention Score of 1.7. This one scored the same or higher as 2 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,766 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
